The effect of DPP-4 inhibition to improve functional outcome after stroke is mediated by the SDF-1α/CXCR4 pathway

Fausto Chiazza1*, Harald Tammen4, Hiranya Pintana1, Grazyna Lietzau1, Massimo Collino3, Thomas Nyström1, Thomas Klein2, Vladimer Darsalia1* and Cesare Patrone1*

Abstract

Background: Dipeptidyl peptidase-4 (DPP-4) inhibitors (gliptins) are approved drugs for the treatment of hyperglycemia in patients with type 2 diabetes. These effects are mainly mediated by inhibiting endogenous glucagon-like peptide-1 (GLP-1) cleavage. Interestingly, gliptins can also improve stroke outcome in rodents independently from GLP1. However, the underlying mechanisms are unknown. Stromal cell-derived factor-1α (SDF-1α) is a DPP-4 substrate and CXCR4 agonist promoting beneficial effects in injured brains. However, SDF-1α involvement in gliptin-mediated neuroprotection after ischemic injury is unproven. We aimed to determine whether the gliptin linagliptin improves stroke outcome via the SDF-1α/CXCR4 pathway, and identify additional effectors behind the efficacy.

Methods: Mice were subjected to stroke by transient middle cerebral artery occlusion (MCAO). Linagliptin was administered for 3 days or 3 weeks from stroke onset. The CXCR4-antagonist AMD3100 was administered 1 day before MCAO until 3 days thereafter. Stroke outcome was assessed by measuring upper-limb function, infarct volume and neuronal survival. The plasma and brain levels of active GLP-1, GIP and SDF-1α were quantified by ELISA. To identify additional gliptin-mediated molecular effectors, brain samples were analyzed by mass spectrometry.

Results: Linagliptin specifically increased active SDF-1α but not glucose-dependent insulinotropic peptide (GIP) or GLP-1 brain levels. Blocking of SDF-1α/CXCR4 pathway abolished the positive effects of linagliptin on upper-limb function and histological outcome after stroke. Moreover, linagliptin treatment after stroke decreased the presence of peptides derived from neurogranin and from an isoform of the myelin basic protein.

Conclusions: We showed that linagliptin improves functional stroke outcome in a SDF-1α/CXCR4-dependent manner. Considering that Calpain activity and intracellular Ca2+ regulate neurogranin and myelin basic protein detection, our data suggest a gliptin-mediated neuroprotective mechanism via the SDF-1α/CXCR4 pathway that could involve the regulation of Ca2+ homeostasis and the reduction of Calpain activity. These results provide new insights into restorative gliptin-mediated effects against stroke.

Keywords: Gliptins, DPP-4 inhibitors, Linagliptin, CXCR4/SDF-1α, Stroke, MCAO, Diabetes
Background
Dipeptidyl-peptidase 4 (DPP-4) inhibitors (gliptins) are oral antidiabetic drugs used to treat type 2 diabetes mellitus (T2D). Gliptins mediate their anti-diabetic effects by primarily inhibiting degradation of endogenous glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP), resulting in prolongation of postprandial insulin secretion [1]. Recent research has shown that gliptins can also reduce stroke-induced brain damage in animal models in presence or absence of diabetes [2]. Furthermore, several reports have shown that gliptins mediate positive pleiotropic effects in animal models of Alzheimer's disease (AD) [3–7] and in diabetic patients with AD [8]. The role of SDF-1α in cerebral ischemic development [19, 21]. Furthermore, the levels of SDF-1α were determined in serum and brain tissues using an enzyme-linked immunosorbent assay (ELISA; see below).

Whereas other studies have demonstrated positive effects by blocking the SDF-1α/CXCR4 pathway in the recovery phase after stroke [25, 26].

In the present study, we investigated whether protective effects of linagliptin after stroke are mediated via SDF-1α by blocking CXCR4 with the selective CXCR4 antagonist AMD3100. Additionally, by using tandem mass spectrometry, we identified effectors putatively involved in gliptin-mediated effects.

Methods
Animals and experimental groups
Animals were housed on a 12 h light/dark cycle with ad libitum access to food/water. Experiments were conducted in accordance with the Guidelines for Care and Use of Laboratory Animals published by US National Institute of Health (Eighth edition, 2011). 101 adult male C57bl6/j mice were used in 4 studies.

Study 1 (to establish an experimental setting to study the effects of linagliptin [27] on functional and histological outcomes after stroke)
To determine whether linagliptin reduces ischemic tissue damage and improves functional outcome when given after experimental stroke, 16 mice were subjected to transient middle cerebral artery occlusion (MCAO, see below) and treated with linagliptin (n = 9) or vehicle (natrosol n = 7). The first week, linagliptin was administered once daily per oral gavage at 10 mg/kg/bw beginning the day of stroke onset. During the next 2 weeks, to diminish per oral gavage-induced stress, mice received linagliptin mixed with standard laboratory chow at a concentration of 83 mg linagliptin pro kg chow. At this concentration, the plasma levels of linagliptin reach approximately 50–100 nM [28], equal to an estimated daily intake of 5–8 mg/kg/bw. Both regimes of administration were efficacious in the brain in previous studies [12, 13, 29, 30]. Mice were killed 3 weeks after MCAO.

Motor function (see below) was assessed before, 3 days and 3 weeks after MCAO.

Study 2 (to quantify active GIP, GLP-1 and SDF-1α after sustained linagliptin treatment)
To determine whether linagliptin treatment up-regulates active GLP-1, active GIP and active SDF-1α in the brain, 19 mice were given linagliptin (n = 10, following the same administration protocol of study 1) or vehicle (natrosol n = 9) daily. Mice were killed after 3 weeks and brain tissues were isolated. Active GLP-1, active GIP and active SDF-1α were determined in serum and brain tissues using an enzyme-linked immunosorbent assay (ELISA; see below).
Study 3 (to determine the potential role of the SDF-1α/CXCR4 pathway in linagliptin-mediated efficacy in the acute phase after stroke)

To determine whether the improved stroke outcome after linagliptin treatment was mediated by the SDF-1α/CXCR4 pathway, 58 mice were subjected to MCAO and treated with linagliptin (10 mg/kg/bw, per oral, n = 19), AMD3100 (5 mg/kg/bw, intraperitoneal n = 11; [31]) AMD3100 + linagliptin (n = 11) or vehicle (natriosol n = 17) for 3 days and sacrificed thereafter. AMD3100 is a strong, almost irreversible antagonist of CXCR4 [32]. To maximally block the effect of CXCR4 on the acute phase after stroke, AMD3100 was given starting from 1 day before MCAO. Subsequently, immunohistological measurements of ischemic brain damage were performed. All animals were tested for motor function before and 3 days after MCAO.

Study 4 (to identify linagliptin-mediated effectors in the acute phase after stroke by mass spectrometry)

For mass spectrometric analysis, 8 mice subjected to stroke from Study 3 and treated with linagliptin (10 mg/kg/bw, per oral, n = 5) or vehicle (n = 3) were employed. Additional 8 naïve mice were treated with linagliptin (10 mg/kg/bw, per oral, n = 4) or vehicle (n = 4). All mice were sacrificed after 3 days. Brain tissues were isolated, frozen and analyzed by mass spectrometry.

A representative illustration of study design is provided in Additional file 1: Figure S1.

Middle cerebral artery occlusion (MCAO)

The intraluminal filament technique was used [33]. Briefly, animals were anesthetized using 1.5% isoflurane, carotid arteries on the left side were exposed, the external carotid was ligated and temporary sutures were placed over the common carotid artery. Through a small incision in the external carotid artery, a 7–0 monofilament coated with silicone was advanced through the internal carotid artery until it blocked the origin of the middle cerebral artery. When the filament had been positioned, wounds were closed and the anesthesia was discontinued. After 30 min of occlusion, the mice were anesthetized again, the filament was withdrawn and ligatures removed from the common carotid artery. Body temperature was maintained at 37–38 °C with a heated pad during surgery. The mice were then transferred to a heated box where they regained wakefulness and were kept there for 2 h.

Assessment of motor function

Motor performance was assessed using forepaw grip strength test [34] before MCAO, 3 days and 3 weeks after MCAO. Briefly, animals were allowed to grasp the handlebar connected to a force meter and gently dragged backward until the grip was released. 10 trials were performed and the highest values recorded. Grip strength of left and right forepaws was measured separately and motor asymmetry was determined by the left to right forepaw strength ratio. The left to right forepaw strength ratio for each mouse before MCAO was measured and used for normalization for post MCAO ratios.

Immunohistochemistry

Animals were deeply anesthetized with sodium pentobarbital and transcardially perfused with saline followed by 4% ice-cold paraformaldehyde. Brains were extracted, post-fixed in 4% paraformaldehyde at 4 °C overnight and submerged in 20% sucrose in phosphate buffer until they sank. 50 µm-thick coronal sections were cut using a sliding microtome and stained as free-floating sections. The details of the immunohistochemistry, and infarct volume and cell quantifications have been recently described [12, 13] and are provided in Additional file 1.

All tests and procedures were performed by an experimenter blinded to the experimental groups.

Determination of active GLP-1, active GIP, active SDF-1α

Mice were deeply anesthetized with sodium pentobarbital and transcardially perfused with cold saline. Brains were removed and midbrains with overlaying cortex dissected and snap frozen.

Determination of active GLP-1 (K150JWC-1, Mesoscale, Gaithersburg, USA) and active GIP (Immuno-Biological Laboratories, IBL 27724) was performed based on manufactures instructions. Active SDF-1α was detected as described by Fadini et al. [35].

Liquid chromatography and mass spectrometry

Details on liquid chromatography and mass spectrometry are shown in Additional file 1.

Statistics

Statistical analyses were performed using the unpaired t test with Welch’s correction (Study 1, 2), one-way ANOVA, followed by the Holm–Sidak’s multiple comparisons test (Study 3). For MS data receiver-operating characteristics (ROC) including the area under the curve (AUC) were calculated and corresponding p-values were determined using an unpaired t test with Welch’s correction (Study 4). Differences between groups were considered statistically significant when p < 0.05. Data are presented as mean ± SD.

Results

Sustained post-ischemic treatment with linagliptin improves motor function and reduces tissue damage after MCAO (Study 1)

The effect of linagliptin treatment on motor function was evaluated 3 days and 3 weeks after MCAO. 3 days after
MCAO, linagliptin-treated mice exhibited significantly smaller motor impairment in comparison to control mice (20% decrease in grip strength vs. 30% of that of vehicle group) (Fig. 1a). After 3 weeks, as expected [36], both groups had recovered motor performance to pre-stroke levels (Fig. 1b). The infarct volume (depicted in Fig. 1d) was evaluated 3 weeks after MCAO and showed a significant decrease (approximately 40% smaller) in linagliptin-treated mice (Fig. 1c).

**Treatment with linagliptin increases levels of active SDF-1a, but not of active GLP-1 and active GIP in the brain (Study 2)**

The results showed that sustained linagliptin treatment significantly increased levels of all three peptides in serum (Fig. 2a–c). However, the treatment had no effect on levels of active GLP-1 and active GIP (Fig. 2d, e respectively), but led to a significant increase (approximately 50%) of active SDF-1α (Fig. 2f) in brain homogenates.
AMD3100 decreases positive linagliptin effects on motor function and tissue damage in the acute phase after stroke (Study 3)

In Study 1 (see Fig. 1a), linagliptin showed a strong effect in improving upper-limb function at Day 3 after stroke. To test the potential involvement of the SDF-1α/CXCR4 pathway on this beneficial effect mediated by linagliptin, AMD3100 (specific antagonist of the SDF-1α/CXCR4) was administered from Day 1 before stroke until this time point. Moreover, the study was terminated at Day 3 after stroke to avoid the potential global side effects of chronic CXCR4 blocking. The results show that AMD3100 completely prevented the improvement of motor function induced by linagliptin (Fig. 3a). Moreover AMD3100 reduced the effect of linagliptin on histological outcome in the cortex (Fig. 3d). The neuroprotective effect of 3-days linagliptin treatment (based on histological analyses) was smaller as compared to 3-weeks treatment in Study 1 and was undetectable by ischemic volume measurements (Fig. 3b) or by quantifying surviving NeuN+ neurons in the striatum (Fig. 3c). This was probably due to a shorter linagliptin administration in comparison with Study 1 where the mice were treated for 3 weeks after stroke before sacrifice.

Tandem mass spectrometry (Study 4)

We could not detect linagliptin in the brain under our experimental conditions.

47 differentially occurring peptides between groups from 16 different precursor proteins were identified (Table 1). Of these, the most frequent peptides originated from glyceraldehyde-3-phosphate dehydrogenase (G3P), neurogranin (NEUG) and an isoform of myelin basic protein (MBP).

G3P is a key cytosol enzyme in glycolysis. Linagliptin stroke (LS) and vehicle stroke (VS) groups showed higher
Fig. 3 Effect of AMD3100 and linagliptin on motor function and tissue damage after MCAO.

a Forepaw grip strength at Day 3 after MCAO.  
b Ischemic volume at Day 3 after MCAO.  
c The number of surviving neurons in the striatum and cortex at Day 3 after MCAO.  
ed Representative photomicrographs of brain sections (NeuN immunostained) used in the quantitative analyses. Solid black line denotes the area of the stroke infarct volume measurement. Solid white line denotes the area of decreased neuronal density after MCAO. Dashed black line denotes the area of neuronal quantification by stereology methods. One-Way ANOVA followed Holm–Sidak’s multiple comparisons test, mean ± SD. * and ** denote p < 0.05 and p < 0.01 respectively and indicate the statistically significant difference over the vehicle group.
### Table 1  List of identified peptides

| UniProt name     | Protein name                        | Sequence                                      | From–to   |
|------------------|-------------------------------------|-----------------------------------------------|-----------|
| 1433B_MOUSE      | 14-3-3 protein beta/alpha           | L.WTSENQGDEGDAGEGEN.-                        | 230–246   |
| 1433Z_MOUSE      | 14-3-3 protein zeta/delta           | L.WTSDTQGDEAEAGEGEN.-                        | 228–245   |
| RLA2_MOUSE       | 60S acidic ribosomal protein P2     | -M.YRSVYLLAALGGN.S                          | 1–15      |
| ATPB_MOUSE       | ATP synthase subunit beta, mitochondrial | A.AQASAAAPKAGTATGRIVA.V                     | 48–65     |
| ATPB_MOUSE       | ATP synthase subunit beta, mitochondrial | Y.AAQAASAAPKAGTATGRIVA.V                     | 47–65     |
| ATPSH_MOUSE      | ATP synthase subunit d, mitochondrial | M.AGRKLAKTIDWSVF+-Acetyl (N-term)            | 2–16      |
| KCRB_MOUSE       | Creatine kinase B-type              | L.IEMEQRLEQGQAIDDLMPAQK.-                    | 361–381   |
| IF4H_MOUSE       | Eukaryotic translation initiation factor 4H | N.SAIFGGARPREEVQKEQ.E                       | 230–248   |
| G3P_MOUSE        | Glyceraldehyde-3-phosphate dehydrogenase | M.RVVDLMAYMASKE.-                           | 321–333   |
| G3P_MOUSE        | Glyceraldehyde-3-phosphate dehydrogenase | M.FQYDSTHGKFNGTVKAEN.G                     | 45–62     |
| G3P_MOUSE        | Glyceraldehyde-3-phosphate dehydrogenase | L.ISWYNESNGSRVVDLLMAYMASKE.                 | 309–333   |
| G3P_MOUSE        | Glyceraldehyde-3-phosphate dehydrogenase | M.VKVGVNGFGRIGRLVTRA.A                      | 2–19      |
| G3P_MOUSE        | Glyceraldehyde-3-phosphate dehydrogenase | M.VKVGVNGFGRIGRLVTR.                        | 2–17      |
| DPYL2_MOUSE      | Dihydropyrimidase-related protein 2 | S.SAKTSPAKQQAPVRNL.H.Q                      | 518–535   |
| EAA2_MOUSE       | Excitatory amino acid transporter 2 | M.ASTEGANNMPKQVEVRMHDHLSLS.+acetyl (N-term) | 2–24      |
| MBP_MOUSE        | Myelin basic protein                | M.ASQRPSRQSKYLTASA+-acetyl (N-term)         | 2–16      |
| MBP_MOUSE        | Myelin basic protein                | M.ASQRPSRQSKYLTASA+-acetyl (N-term)         | 2–17      |
| MBP_MOUSE        | Myelin basic protein                | M.ASQRPSRQSKYLTAS.T+-acetyl (N-term)         | 2–18      |
| MBP_MOUSE        | Myelin basic protein                | M.ASQRPSRQSKYLTAST.M+-acetyl (N-term)        | 2–19      |
| MBP_MOUSE        | Myelin basic protein                | M.ASQRPSRQSKYLTASTMDH+-acetyl (N-term); oxidation (M) | 2–21      |
| MBP_MOUSE        | Myelin basic protein                | M.ASQRPSRQSKYLTASTMDH.A+-acetyl (N-term); oxidation (M) | 2–22      |
| MAG_MOUSE        | Myelin-associated glycoprotein      | M.ASQRPSRQSKYLTASTMDH.A+-acetyl (N-term)     | 2–23      |
| NEUG_MOUSE       | Neurogranin                         | K.GPGPGGPPGAGARG.G                          | 55–69     |
signal intensities of 5 unique G3P-derived peptides in comparison to linagliptin non-stroke (LC) and vehicle non-stroke (VC) groups (Table 1).

NEUG is primarily expressed in the brain [37] and is the main postsynaptic protein regulating the availability of Calmodulin by binding to it in the absence of Ca^{2+} [38]. Here, signal intensities of 6 unique peptides were lower in LS in comparison to the remainder of samples (VS, LC, VC) (Fig. 4).

| UniProt name | Protein name | Sequence | From–to |
|--------------|--------------|----------|---------|
| NEUG_MOUSE  | Neurogranin  | PGPGGAGGARGGAGGGPSGD- | 59–78   |
| NEUG_MOUSE  | Neurogranin  | RGKPGPGGPARGGAGGGPS  | 54–75   |
| NEUG_MOUSE  | Neurogranin  | KGPGGAPGARGGAGGGPSGD- | 55–78   |
| NEUG_MOUSE  | Neurogranin  | RGKPGPGGPARGGAGGGPSGD- | 54–78   |
| NEUG_MOUSE  | Neurogranin  | GRKPGPGGPARGGAGGGPSGD- | 53–78   |
| SNG3_MOUSE  | Synaptogyrin-3 | AYPGVSGVEGETYQ | 193–208 |

The table depicts the UniProt name, the precursor protein name, the amino acid sequence and the amino acid range of identified peptides. The dot within the sequence denotes the cleavage site. The top part list peptides found to possess significant higher signal intensities in stroke samples and the bottom part peptides possessing significant lower signal intensities in linagliptin-stroke samples.
MBP is one of the most abundant protein components of the myelin membrane in the CNS [39] which also binds Calmodulin [40]. LS showed lower signal intensities of 15 unique peptides in comparison to the remainder of samples (VS, LC, VC), (Fig. 5).

**Discussion**

The primary objective of this study was to determine whether the improved outcome after stroke following gliptin treatment is SDF-1α/CXCR4-dependent. We showed that linagliptin improves functional stroke outcome in a SDF-1α/CXCR4-dependent manner. Secondly, we demonstrated that linagliptin after stroke decreased the presence of peptides derived from NEUG and MBP.

Different research groups have shown that gliptins reduce brain damage and improve functional parameters after stroke in various animal models independently from a T2D background (reviewed in [2, 41, 42]). A few large clinical studies with gliptins in diabetic patients have investigated the potential of these drugs to decrease cardiovascular incidence (including stroke) and death with neutral results (reviewed by Nauck et al. [10]). However, since the efficacy measures in these clinical studies (stroke incidence and death) did not address functional outcomes after stroke, further clinical studies are needed to evaluate the potential of these drugs to improve functional stroke outcome [9]. Interestingly, the ongoing CARMELINA study with linagliptin (Clinicaltrials.gov; NCT01897532) contains a post-stroke functional study using the modified Rankin scale to assess stroke-induced disability approximately 1 week following stroke and at ~3 months after stroke-onset. Preclinical data indicating that gliptins can improve stroke outcome in the post-stroke recovery phase have been recently shown by Ma et al. in a model of transient cerebral ischemia induced by bilateral common carotid artery occlusion. The study showed that sustained linagliptin treatment...
after cerebral ischemia counteracted cognitive impairment and brain atrophy, independently from the regulation of glycemia [43]. This study is remarkable because their model allows extending the observation period for several weeks after artery occlusion thus evaluating effects of sustained gliptin treatment in the post-stroke recovery phase. Our results confirm that sustained linagliptin treatment after stroke is necessary to improve stroke outcome while a single acute bolus administration of linagliptin at stroke time was ineffective (previously published in [13]).

Clinical data suggesting that gliptins can exert beneficial effects in the damaged brain do also exist. Isik et al. recently showed that a treatment for 6 months with sitagliptin was associated with improvement of cognitive function in elderly diabetic patients with and without Alzheimer’s disease [8]. To support the translation of pre-clinical functional outcome stroke studies with gliptins to clinical settings, it is helpful to identify mechanisms of action of this class of drugs in the brain.

The antidiabetic effects of gliptins are mediated via GIP and GLP-1 regulation, but other incretin-independent mechanisms may also be involved [15]. We recently showed that mice lacking the GLP-1-receptor exhibit improved stroke outcome after linagliptin treatment [13]. Recent research by Han et al. has shown that a dual agonist targeting both GLP-1 and GIP receptors promoted stronger neuroprotection against stroke than the GLP-1 analogue Val(8)-GLP-1(glu-PAL) alone thus suggesting a mechanism mediated by GIPR activation [14]. Further studies employing mice lacking GIP and/or GIPR are needed to investigate this hypothesis. However, we showed in this study that brain GIP levels were unaffected by linagliptin treatment. Furthermore our previous study using mice lacking the GLP-1R [13] showed that linagliptin can improve stroke outcome independently from GLP-1R. Although we cannot rule out peripheral effects mediated by GIP, this suggests that the positive effect of gliptins on stroke outcome may not be necessarily related to incretins.

The DPP-4 substrate SDF-1α plays a pivotal role in the brain, as it regulates neurovascular remodeling after stroke [23–26]. The beneficial effects of SDF-1α were also shown in rats after traumatic brain injury [44] and in an AD animal model, where SDF-1α treatment decreased beta-amyloid deposition [45]. Of relevance for our study, recent research in myocardial infarction (MI) has shown that increased SDF-1α by gliptins mediates protective effects against MI through anti-apoptotic effects [46, 47].

Our results show that sustained linagliptin treatment increases active SDF-1α in brain parenchyma. Importantly, by sustained blocking of the SDF-1α/CXCR4 pathway, linagliptin-mediated effects on functional and histological outcomes after stroke were diminished. This indicates that improved stroke outcome by linagliptin occurs via the activation of the SDF-1α/CXCR4 pathway. DPP-4 activity was similarly inhibited in linagliptin, and linagliptin/AMD 3100-treated animals (data not shown). Therefore, the inhibitory effect of AMD 3100 over linagliptin on stroke outcome could not be linked to altered DPP-4 activity between the groups. The pro versus adverse effects of SDF-1α after gliptins treatments in diabetic complications has been recently deeply discussed [48, 49]. Our results suggest that, at least when it comes to post-stroke treatment, the activation of the SDF-1α/CXCR4 pathway promotes beneficial effects. Two weaknesses of this set of results that need to be addressed in the future are: (1) the fact that the study was performed in naïve mice and that a diabetic background could have affected the outcome; (2) it is unclear why the SDF-1α/CXCR4 pathway seems to be more involved in the functional (Fig. 3a) rather than in the structural recovery (Fig. 3d). Nevertheless, previous studies show that SDF-1α is involved in axonal path finding, outgrowth and branching; all functions involved in functional recovery [19].

The effects of linagliptin to reduce the injury after stroke could involve the neuroprotective, non-neurogenic rapid effects of neural progenitor cells (NPCs) [50] since CXCR4 inhibition in NPCs leads to failure of newborn neurons to localize to the ischemic brain tissue [19]. The linagliptin effects via SDF-1α/CXCR4 to reduce the brain injury after stroke could also be mediated by the regulation of neovascularization through endothelial progenitor cells (EPCs) [51] since gliptins increase ischemic angiogenesis by preserving EPCs function [52]. Moreover, SDF-1α is known to be involved in the recruitment to the injury region of EPCs [19]. This action of SDF-1α on EPCs could contribute to explain the stronger efficacy of linagliptin to improve stroke outcome after 3 weeks versus 3 days of treatment as it has been shown that EPCs recruitment occurs 2 weeks after ischemic injury [53]. New studies should be performed in the future to demonstrate this hypothesis.

Finally, the SDF-1α/CXCR4 pathway could play a role in functional regulation of the brain vasculature, since linagliptin improves endothelium-dependent relaxation independently of glucose regulation [28]. Furthermore, SDF-1α/CXCR4 signaling activates endothelial nitric oxide synthase [32] which is a key enzyme maintaining homeostasis by inducing vaso dilatation and whose impairment is implicated in the pathogenesis of stroke [54]. These results support the possibility that the positive effects of gliptins on stroke outcome could also occur via increased blood perfusion in collateral vessels in the
**penumbra** region of ischemic brains thus mitigating the degenerative effects of MCAO.

To further elucidate effects of linagliptin after stroke, we analyzed brain tissue samples by mass spectrometry. We did not detect linagliptin under our experimental conditions in agreement with previous published data demonstrating that linagliptin does not cross the blood brain barrier under physiological conditions [55]. However due to MALDI-TOF/TOF mass spectrometry conditions, we cannot rule out that traces of linagliptin could enter the brain under stroke conditions.

Peptides that are generated by proteolytic processing of larger precursor proteins can be regarded as surrogate markers for expression levels of proteins or peptidase activity [56]. In samples from animals subjected to MCAO, peptides derived from G3P were observed. We speculate that these peptides reflect a direct effect of ischemia causing release of substances from the cytosol due to cell membrane instability.

The analysis further revealed that NEUG peptides exhibit lower signal intensities in stroke tissue samples from animals treated with linagliptin (Fig. 4 and Figure S2 in Additional file 1). These results might suggest lowered expression of NEUG or a reduced susceptibility to proteolytic processing of free NEUG not bound to Calmodulin.

The protein level or proteolytic cleavage pattern of an isoform of MBP appeared to be also altered (Fig. 5). The observed pattern of MBP peptides (Figure S3 in Additional file 1) shows a very good fit to Calpain processing based on the substrate and observed cleavage sites according to MEROPS, a database of proteolytic enzymes [57]. We presume that the observed MBP peptides do not represent breakdown products due to stroke since no significant difference between VS and LC/VC samples was present. Rather the low intensities or even diminished presence of MBP peptides in samples from mice subjected to stroke and treated with linagliptin, mirror altered proteolytic activities or insusceptibility to processing of MBP due to e.g. Calmodulin binding [40] as a second-tier effect (see below) analog to NEUG. These peptides are not affected in samples from linagliptin-treated control mice, which is in line with the observation that linagliptin does not cross the blood brain barrier under physiological conditions [55].

These data suggest that the proteolytic processing products of two Calmodulin-binding proteins exhibit significantly lower signal intensities in brain samples after stroke under linagliptin treatment either due to altered expression, insusceptibility to proteolytic processing because of Calmodulin binding and/or altered activity of proteases like Calpain. Since presence of free NEUG and MBP and/or altered Calpain activity are all dependent on intracellular Ca$^{2+}$ concentration [38, 58], we hypothesize that linagliptin treatment, presumably through SDF-1α, could affect Ca$^{2+}$ homeostasis. Indeed, a study by Nicolai et al. [59], showed that SDF-1α selectively inhibits the expression of NR2B, a regulatory subunit of NMDA receptor, altering NMDA-induced Ca$^{2+}$ responses associated with neuronal death, while promoting pro-survival pathways. However further studies (intracellular Ca$^{2+}$ measurement, Calpain activity) are necessary to verify or falsify the proposed mechanism.

**Conclusions**

T2D patients have more than double the risk of ischemic stroke [60]. The surviving stroke patients with T2D often show poor functional recovery and even further neurological deterioration in comparison to non-diabetics. This holds true even after adjusting for stroke severity and patients’ age [61]. Remarkably, this important problem has been poorly investigated clinically in comparison to several studies focused on why the incidence of stroke in T2D patients is higher than in non-diabetics. Therefore, a treatment with gliptins in the acute phase after stroke could be beneficial for T2D patients based on preclinical studies. However, more research on the mechanisms at the basis of gliptins action is needed to exploit their potential properties. We did demonstrate the involvement of the SDF-1α/CXCR4 pathway in improved stroke outcomes after linagliptin treatment. Our data also suggest a potential gliptin-mediated neuroprotective mechanism that involves NEUG and MBP through the regulation of Ca$^{2+}$ homeostasis and the reduction of Calpain activity. Although these results provide a first glance of gliptin actions in the brain only, they represent new insights on effects of these anti-hyperglycemic drugs against decreased functional outcome after stroke.

**Additional file**

Additional file 1. Additional methodological information and 2 additional results figures.

**Authors’ contributions**

FC performed immunohistochemistry studies and stereology analysis; acquired and processed images and figures; contributed to discussion, and wrote the manuscript. HT performed the mass spectrometry experiments, contributed to discussion and edited the manuscript. HP and GL contributed to discussion and helped with the immunohistochemistry experiments. MC provided expertise and resources and edited the manuscript. TN provided expertise and resources, contributed to discussion and edited the manuscript. TK conceived the research plan, provided expertise in DPP-4 inhibitors, coordinated ELISA studies, contributed to discussion, and edited the manuscript. VS designed, conceived and performed the stroke experiments, contributed to discussion and wrote the manuscript. SP conceived, designed, and coordinated the research plan, contributed to discussion and wrote the manuscript. All authors read and approved the final manuscript.
Author details
1 Department of Clinical Science and Education, Södersjukhuset, Internal Medicine, Karolinska Institutet, 118 83 Stockholm, Sweden. 2 Department of CardioMetabolic Diseases Research, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany. 3 Department of Drug Science and Technology, University of Turin, Torino, Italy. 4 PXBioVision GmbH, Hannover, Germany.

Acknowledgements
We thank Dr. Fuad Bahram (Södersjukhuset) for technical assistance and Dr. Hans Pettersson for advice on statistical analyses.

Competing interests
Work in our laboratory is supported by Boehringer Ingelheim Pharma GmbH & Co. Thomas Klein is employed at Boehringer Ingelheim Pharma GmbH & Co. Thomas Nystrom has received unrestricted grants from AstraZeneca and consultancy fees from Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Merck and Sanofi-Aventis.

Availability of data and materials
The datasets used and analyzed in our study are available from the corresponding author on reasonable requests.

Consent for publication
Not applicable.

Ethics approval and consent to participate
Not applicable.

Funding
Financial support was provided by The Swedish Heart–Lung Foundation, Diabetesfonden, Konung Gustaf V’s och Drottning Victoria’s Frimurarstiftelse, the NovoNordisk foundation, European Foundation for the Study of Diabetes (EFSDF) Albert Renold Travel Fellowship Programme to Dr. Fausto Chiazza, Åhlén Stiftelse, Stohnes Stiftelse, O. E. och Edla Johanssons Stiftelse, Magnus Bergvalls Stiftelse, STROKE Riksförbundet, Tornspiran stiftelse, Gamla Tjänarinnor Stiftelse, Sysskenen Svensson Stiftelse, Boehringer Ingelheim Pharma GmbH & Co. KG and by the regional agreement on medical training and clinical research (ALF) between Stockholm County Council and the Karolinska Institutet (KI).

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 26 February 2018 Accepted: 5 April 2018
Published online: 19 May 2018

References
1. Deacon CF, Holst JJ. Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: comparison, efficacy and safety. Expert Opin Pharmacother. 2013;14(15):2047–58.
2. Darsalia V, Klein T, Nystrom T, Patrone C. Glucagon-like receptor 1 agonists and DPP-4 inhibitors: anti-diabetic drugs with anti-stroke potential. Neuropsychopharmacology. 2017. https://doi.org/10.1016/j.
3. Chalichem NSS, Goniugunta C, Krishnamurthy PT, Duraiswamy B. DPP-4 inhibitors can be a drug of choice for type 3 diabetes: a mini review. Am J Diabetes Obes Metab. 2015;5(2):403–13.
4. Hasagawa Y, Hayashi K, Takemoto Y, Cheng C, Takane K, Lin B, Komohara Y, Kim-Mitsuhashi S. DPP-4 inhibition with linagliptin ameliorates the progression of premature aging in klotho−/− mice. Cardiovasc Diabetol. 2017;16(1):154.
5. Hasegawa Y, Hayashi K, Takemoto Y, Cheng C, Takane K, Lin B, Komohara Y, Kim-Mitsuhashi S. DPP-4 inhibition with linagliptin ameliorates the progression of premature aging in klotho−/− mice. Cardiovasc Diabetol. 2017;16(1):154.
6. Kosaraju J, Holsinger RMD, Guo L, Tam KY. Linagliptin, a dipeptidyl peptidase-4 inhibitor, mitigates cognitive defects and pathology in the 3xTg-AD mouse model of Alzheimer’s disease. Mol Neurobiol. 2017;54(8):6074–84.
7. D’Amico M, Di Filippo C, Marfella R, Abbatecola AM, Ferraccio F, Rossi F, Paolillo G. Long-term inhibition of dipeptidyl peptidase-4 in Alzheimer’s prone mice. Exp Gerontol. 2010;45(3):202–7.
8. Isik AT, Soysal P, Yay A, Usarel C. The effects of sitagliptin, a DPP-4 inhibitor, on cognitive functions in elderly diabetic patients with or without Alzheimer’s disease. Diabetes Res Clin Pract. 2017;123:192–8.
9. Darsalia V, Larsson M, Klein T, Patrone C. The high need for trials assessing functional outcome after stroke rather than stroke prevention with GLP-1 agonists and DPP-4 inhibitors. Cardiovasc Diabetol. 2018;17(1):32.
10. Nauck MA, Meier JJ, Cavender MA, Abd EI, Azz M, Drucker DJ. Cardiovascular actions and clinical outcomes with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Circulation. 2017;136(9):849–70.
11. Barkas F, Elisaf M, Tsimihodimos V, Milionis H. Dipeptidyl peptidase-4 inhibitors and protection against stroke: a systematic review and meta-analysis. Diabetes Metab. 2017;43(1):1–8.
12. Darsalia V, Ortsater H, Larsson M, Klein T, Patrone C. The DPP-4 inhibitor linagliptin counteracts stroke in the normal and diabetic mouse brain: a comparison with glimepiride. Diabetes. 2013;62(4):1289–96.
13. Darsalia V, Larsson M, Lietzau G, Nathanson D, Nystrom T, Klein T, Patrone C. Cilipins-mediated neuroprotection against stroke requires chronic pre-treatment and is glucagon-like peptide-1 receptor independent. Diabetes Obes Metab. 2016;18:537–41.
14. Han L, Holscher C, Xue GF, Li G, Li D. A novel dual-glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptor agonist is neuroprotective in transient focal cerebral ischemia in the rat. NeuroReport. 2016;27(1):23–32.
15. Omar B, Ahern B. Pleiotropic mechanisms for the glucose-lowering action of DPP-4 inhibitors. Diabetes. 2014;63(7):2196–202.
16. Shannon RP. DPP-4 inhibition and neuroprotection: do mechanisms matter? Diabetes. 2013;62(4):1029–31.
17. Andersen ES, Deacon CF, Holst JJ. Do we know the true mechanism of action of the DPP-4 inhibitors? Diabetes Obes Metab. 2017. https://doi.org/10.1111/dom.13018.
18. Rostene W, Kitabgi P, Parsadaniantz SV. Chemokines: a new class of neuromodulator? Nat Rev Neurosci. 2007;8(11):895–903.
19. Cheng X, Wang H, Zhang X, Zhao S, Zhou M, Xu X, Zhao C, Tang C, Weng T. The role of SDF-1/CXCR4/CXCR7 in neuronal regeneration after cerebral ischemia. Front Neurosci. 2017;11:590.
20. Doitsidou M, Reichman-Fried M, Stebler J, Koprunner M, Dorries J, Meyer D, Esugerra CV, Leung T, Raz E. Guidance of primordial germ cell migration by the chemokine SDF-1. Cell. 2002;11(5):647–59.
21. Pujol F, Kitabgi P, Boudin H. The chemokine SDF-1 differentially regulates axonal elongation and branching in hippocampal neurons. J Cell Sci. 2005;118(Pt 5):1071–80.
22. Lasce K, Stellos K, Stransky S, Seizer P, Akcay O, Eschweiler GW, Leyhe T, Gawaz M. Decreased plasma and cerebrospinal fluid levels of stem cell factor in patients with early Alzheimer’s disease. J Alzheimers Dis. 2008;15(3):451–60.
23. Li Y, Huang J, He X, Tang G, Tang YH, Liu Y, Lin X, Lu Y, Yang GY, Wang Y. Postacute stromal cell-derived factor-1alpha expression promotes neurovascular recovery in ischemic mice. Stroke. 2014;45(6):1822–9.
24. Robin AM, Zhang ZG, Wang L, Zhang RL, Kapokowski M, Zhang L, Wang Y, Zhang C, Chopp M. Stromal cell-derived factor 1alpha mediates neural progenitor cell motility after focal cerebral ischemia. J Cereb Blood Flow Metab. 2006;26(1):125–34.
25. Walter HL, van der Maten G, Antunes AR, Wieloch T, Ruscher K. Treatment with AMD3100 attenuates the microglial response and improves outcome after experimental stroke. J Neuroinflamm. 2015;12:24.
26. Huang J, Li Y, Tang Y, Tang G, Yang GY, Wang Y. CXCR4 antagonist AMD3100 protects blood–brain barrier integrity and reduces inflammatory response after focal ischemia in mice. Stroke. 2013;44(1):190–7.
27. Singh-Franco D, McLaughlin-Middlekauff J, Elrod S, Harrington C. The effect of linagliptin on glycaemic control and tolerability in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetes Obes Metab. 2012;14(8):694–708.
28. Kroller-Schoen S, Knorr M, Hausing M, Oelze M, Schuff A, Schell R, Sudowe S, Scholz A, Daub S, Karbach S, et al. Glucose-independent improvement of vascular dysfunction in experimental sepsis by dipeptidyl-peptidase 4 inhibition. Cardiovasc Res. 2012;96(1):1–9.

29. Darsalia V, Oliverling A, Larsson M, Mansouri S, Nathanson D, Nystrom T, Klein T, Sjobalm A, Patrone C. Linagliptin enhances neural stem cell proliferation after stroke in type 2 diabetic mice. Regul Pept. 2014;190:25–31.

30. Lietzau G, Davidsson W, Ostenson CG, Chiazza F, Nathanson D, Pintana H, Skogberg J, Klein T, Nyström T, Darsalia V, et al. Type 2 diabetes impairs odour detection, olfactory memory and olfactory neuroplasticity, effects partly reversed by the DPP-4 inhibitor linagliptin. Acta Neuropathol Commun. 2018;6(1):14.

31. Liu G, Li Z, Gao JL, Wan W, Ganesan S, McDermott DH, Murphy PM. CXCR4 antagonist AMD3100 redistributes leukocytes from primary immune organs to secondary immune organs, lung, and blood in mice. Eur J Immunol. 2015;45(6):1855–67.

32. Chen LH, Advani SL, Thai K, Kabir MG, Sood MM, Gibson M, Yuen DA, Connelly KA, Marsden PA, Kelly DJ, et al. SDF-1/CXCR4 signaling preserves microvascular integrity and renal function in chronic kidney disease. PLoS ONE. 2014;9(3):e92227.

33. Kozumi J, Yoshida Y, Nakazawa T, Omeda G. Experimental studies of ischemic brain edema. 1. A new experimental model of cerebral embolism in rats in which recirculation can be introduced into the ischemic area. Stroke. 1986;17:1–8.

34. Ferrara A, El Bejaoui S, Seyen S, Tirelli E, Plumier JC. The usefulness of antagonists of glucagon-like receptor 1 agonists and DPP-4 inhibitors: potential therapies for the treatment of stroke. J Clin Endocrinol Metab. 2016;101(2):748–56.

35. Balkaya M, Krober JM, Rex A, Endres M. Assessing post-stroke behavior in mouse models of focal ischemia. J Cereb Blood Flow Metab. 2013;33(3):330–8.

36. Lista S, Hampel H. Synaptic degeneration and neurogranin in the pathophysiology of Alzheimer’s disease. Expert Rev Neurother. 2017;17(1):47–57.

37. Hoffman L, Chandrasekar A, Wang X, Putkey JA, Vakhnin MN. Neurogranin alters the structure and calcium binding properties of Calmodulin. J Biol Chem. 2014;289(21):14644–55.

38. Deber CM, Reynolds SJ. Central nervous system myelin: structure, function, and pathology. Clin Biochem. 1991;24(2):113–34.

39. Libich DS, Harauz G. Backbone dynamics of the 18.5 kDa isoform of myelin basic protein reveals transient alpha-helices and a Calmodulin-binding site. Biophys J. 2008;94(12):4847–66.

40. Darsalia V, Larsson M, Nathanson D, Klein T, Nyström T, Patrone C, Albeno M, Avogaro A. Acute effects of linagliptin on progenitor cells, monocyte phenotypes, and soluble mediators in type 2 diabetes. J Clin Endocrinol Metab. 2016;101(2):748–56.

41. Libich DS, Harauz G. Backbone dynamics of the 18.5 kDa isoform of myelin basic protein reveals transient alpha-helices and a Calmodulin-binding site. Biophys J. 2008;94(12):4847–66.

42. Fadini GP, Ronora BM, Cappellari R, Menegazzo L, Vedovato M, Iori E, Marescotti MC, Albino M, Avogaro A. Acute effects of linagliptin on progenitor cells, monocyte phenotypes, and soluble mediators in type 2 diabetes. J Clin Endocrinol Metab. 2016;101(2):748–56.

43. Balkaya M, Krober JM, Rex A, Endres M. Assessing post-stroke behavior in mouse models of focal ischemia. J Cereb Blood Flow Metab. 2013;33(3):330–8.

44. Lista S, Hampel H. Synaptic degeneration and neurogranin in the pathophysiology of Alzheimer’s disease. Expert Rev Neurother. 2017;17(1):47–57.

45. Hoffman L, Chandrasekar A, Wang X, Putkey JA, Vakhnin MN. Neurogranin alters the structure and calcium binding properties of Calmodulin. J Biol Chem. 2014;289(21):14644–55.

46. Deber CM, Reynolds SJ. Central nervous system myelin: structure, function, and pathology. Clin Biochem. 1991;24(2):113–34.

47. Libich DS, Harauz G. Backbone dynamics of the 18.5 kDa isoform of myelin basic protein reveals transient alpha-helices and a Calmodulin-binding site. Biophys J. 2008;94(12):4847–66.

48. Darsalia V, Larsson M, Nathanson D, Klein T, Nyström T, Patrone C, Albeno M, Avogaro A. Acute effects of linagliptin on progenitor cells, monocyte phenotypes, and soluble mediators in type 2 diabetes. J Clin Endocrinol Metab. 2016;101(2):748–56.

49. Libich DS, Harauz G. Backbone dynamics of the 18.5 kDa isoform of myelin basic protein reveals transient alpha-helices and a Calmodulin-binding site. Biophys J. 2008;94(12):4847–66.

50. Fadini GP, Ronora BM, Cappellari R, Menegazzo L, Vedovato M, Iori E, Marescotti MC, Albino M, Avogaro A. Acute effects of linagliptin on progenitor cells, monocyte phenotypes, and soluble mediators in type 2 diabetes. J Clin Endocrinol Metab. 2016;101(2):748–56.

51. Sobrino T, Hurtado O, Moro MA, Rodriguez-Yanez M, Castellanos M, Brea D, Molides O, Blanco M, Arenillas JF, Leira R, et al. The increase of circulating endothelial progenitor cells after acute ischemic stroke is associated with good outcome. Stroke. 2007;38(10):2759–64.

52. Dai X, Zeng J, Yan X, Lin Q, Wang K, Chen J, Shen F, Gu X, Wang Y, Chen J, et al. Sitagliptin-mediated preservation of endothelial progenitor cell function via augmenting autophagy enhances ischemic angiogenesis in diabetes. J Cell Mol Med. 2017;21:89–100.

53. Yin Y, Duan J, Guo C, Wei G, Wang Y, Guan Y, Mu F, Yao M, Xi M, Wen A. Danshensu accelerates angiogenesis after myocardial infarction in rats and promotes the functions of endothelial progenitor cells through SDF-1alpha/CXCR4 axis. Eur J Pharmacol. 2017;814:274–82.

54. Srivastava K, Bath PM, Bakytzutu U. Current therapeutic strategies to mitigate the eNOS dysfunction in ischaemic stroke. Cell Mol Neurobiol. 2012;32(3):319–36.

55. Fuchs H, Binder R, Greisschel A. Tissue distribution of the novel DPP-4 inhibitor BI 1356 is dominated by saturable binding to its target in rats. Biopharm Drug Dispos. 2009;30(5):229–40.

56. Tammen H, Hess R, Rose H, Wienen W, Jost M. Peptidomic analysis of blood plasma after in vivo treatment with protease inhibitors—a proof of concept study. Peptides. 2008;29(12):2188–95.

57. Rawlings ND, Barrett AJ, Finn R. Twenty years of the MEROPS database of proteolytic enzymes, their substrates and inhibitors. Nucleic Acids Res. 2016;44(D1):D343–50.

58. Liu J, Liu MC, Wang KK. Calpain in the CNS: from synaptic function to neurotoxicity. Sci Signal. 2008;1(14):re1.

59. Nicolai J, Burbassi S, Rubin J, Meucci O. CXCL12 inhibits expression of the p75NTR receptor in microglia. J Cell Mol Med. 2017;21:89–100.

60. Luitse MJ, Biessels GJ, Rutten GE, Kappelle LJ. Diabetes, hyperglycaemia, and arterial stiffness: a systematic review based on pre-clinical studies. Basic Clin Pharmacol Toxicol. 2018;124(3):283–97.

61. Ullberg T, Zia E, Petersson J, Norrving B. Changes in functional outcome over the first year after stroke: an observational study from the Swedish Stroke Register. Stroke. 2015;46(2):389–94.